TRAVERE THERAPEUTICS, INC. Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount
TRAVERE THERAPEUTICS, INC. (TVTX) had Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount of $10.55 million as of 2014-06-30, per its 10-Q filed 2014-08-14.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized · last filed 2015-07-09
- 2014-06-30: Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $10.55M.
- 2014-03-31: Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $8.40M.
- 2013-12-31: Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $1.11M; Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount as first filed $9.21M.
- 2013-09-30: Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $1.29M.
| Period end | Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount as first filed |
|---|---|---|
| 2014-06-30 | $10.55M 10-Q · filed 2014-08-14 | |
| 2014-03-31 | $8.40M 10-Q · filed 2014-05-15 | |
| 2013-12-31 | $1.11M 10-Q · filed 2014-08-14 | $9.21M 10-K · filed 2014-03-28 |
| 2013-09-30 | $1.29M 10-Q/A · filed 2015-07-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |